Ozempic vs Wegovy vs Mounjaro vs Zepbound: 2026 Comparison Guide

Reviewed by Dr. Donald L. Gates, MD — Bariatric Medicine since 1999

Last updated: June 2026

What Are These Four Medications?

If you’ve been searching for GLP-1 weight loss medications, you’ve almost certainly encountered these four brand names: Ozempic, Wegovy, Mounjaro, and Zepbound. They appear in the same conversations and are often conflated, but they are not interchangeable — and understanding the differences is important before talking to a physician.

At the broadest level, all four belong to a class of medications that act on the GLP-1 receptor — a receptor involved in appetite regulation, insulin secretion, and gastric motility. Ozempic and Wegovy share the same active ingredient: semaglutide. Mounjaro and Zepbound share the same active ingredient: tirzepatide. The brand names differ because the medications were developed for different FDA-approved indications — and that distinction matters clinically and legally.

Side-by-Side Comparison Table

Note: Prices shown are approximate list prices and may differ based on pharmacy, dosage, manufacturer savings programs, and insurance coverage. Clinical trial weight loss figures reflect specific trial populations and should not be interpreted as guaranteed individual outcomes.

Semaglutide: Ozempic and Wegovy

Semaglutide was developed by Novo Nordisk and works by mimicking the action of the naturally occurring GLP-1 hormone. It slows gastric emptying, reduces appetite signaling in the brain, and stimulates insulin release in a glucose-dependent manner.

Ozempic: Approved for Type 2 Diabetes

Ozempic received FDA approval in December 2017 for improving glycemic control in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise. Its approved dosing ranges from 0.25 mg (starter dose, 4 weeks) to a maximum of 2.0 mg weekly.

Important: Ozempic is not FDA-approved for weight loss in people without type 2 diabetes. While physicians may prescribe it off-label for weight management, patients should understand this distinction. In the SUSTAIN-6 trial (a cardiovascular outcomes trial in T2D patients), semaglutide also demonstrated a cardiovascular benefit — but this population had existing cardiovascular disease, not obesity without diabetes.

Wegovy: FDA-Approved for Chronic Weight Management

Wegovy received FDA approval in June 2021 for chronic weight management in adults with a BMI of 30 kg/m² or higher, or 27 kg/m² or higher with at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, dyslipidemia). Wegovy uses the same molecule as Ozempic but is formulated for a higher maintenance dose (2.4 mg weekly) and is specifically approved for weight loss.

In 2024, the FDA also approved Wegovy to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight. As of March 2026, the FDA has approved an extended high-dose formulation (7.2 mg weekly) for adults who tolerate 2.4 mg and need additional weight reduction.

For a full discussion of semaglutide options, visit our semaglutide page and our guide to your first 30 days on semaglutide.

Tirzepatide: Mounjaro and Zepbound

Tirzepatide, developed by Eli Lilly, is a newer molecule that acts simultaneously on two receptors: the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. This dual mechanism is thought to produce greater appetite suppression and metabolic effects than GLP-1 agonism alone — which appears to be reflected in the clinical trial data.

Mounjaro: Approved for Type 2 Diabetes

Mounjaro received FDA approval in May 2022 for improving glycemic control in adults with type 2 diabetes. Like Ozempic, it is not FDA-approved for weight loss as a standalone indication, and using it for weight management in non-diabetic patients is considered off-label use. Its approved doses range from 2.5 mg (starter) to 15 mg weekly.

The SURPASS-2 trial compared tirzepatide to semaglutide 1.0 mg in T2D patients; tirzepatide demonstrated both greater HbA1c reduction and greater body weight reduction in that diabetic population.

Zepbound: FDA-Approved for Chronic Weight Management

Zepbound received FDA approval in November 2023 for chronic weight management in adults with a BMI of 30 kg/m² or higher, or 27 kg/m² or higher with at least one weight-related comorbidity — the same BMI criteria as Wegovy. Zepbound uses the same active ingredient as Mounjaro but carries the weight management indication. The FDA additionally approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity in December 2024.

Our tirzepatide page and our comparison guide discuss how these medications are evaluated for individual patients.

Clinical Trial Evidence at a Glance

All four medications have been studied in large, rigorous Phase 3 trials. The key programs are:

STEP Program (Semaglutide for Weight)

The STEP (Semaglutide Treatment Effect in People with Obesity) program evaluated Wegovy (semaglutide 2.4 mg weekly) across multiple trials. The landmark STEP 1 trial, published in the New England Journal of Medicine in 2021, enrolled 1,961 adults with obesity or overweight without diabetes. At 68 weeks, participants on semaglutide achieved a mean body weight reduction of 14.9% compared to 2.4% for placebo — a difference of 12.4 percentage points. Approximately 86% of semaglutide participants lost at least 5% of body weight, and about one-third lost 20% or more.

SUSTAIN Program (Semaglutide for Diabetes)

The SUSTAIN trials evaluated Ozempic in patients with type 2 diabetes. Weight loss was a secondary outcome; results varied by dose and comparator, typically showing 3–7 kg of additional weight reduction compared to placebo in T2D populations. Cardiovascular outcomes data from SUSTAIN-6 supported the subsequent cardiovascular risk reduction approval for semaglutide.

SURMOUNT Program (Tirzepatide for Weight)

The SURMOUNT trials evaluated Zepbound (tirzepatide) for weight management. In SURMOUNT-1, adults without diabetes achieved mean weight reductions of up to approximately 20.9% from baseline at 72 weeks (at the 15 mg dose). In the SURMOUNT-5 head-to-head trial published in 2025, Zepbound participants lost an average of 20.2% of body weight versus 13.7% with Wegovy at 72 weeks — a difference of approximately 47% greater relative weight loss.

SURPASS Program (Tirzepatide for Diabetes)

The SURPASS trials evaluated Mounjaro in patients with type 2 diabetes. The SURPASS-2 trial compared tirzepatide to semaglutide 1.0 mg, with tirzepatide demonstrating superior outcomes on both glycemic and weight endpoints in that diabetic population.

Important context: Clinical trial results represent averages in controlled research settings. Individual results vary based on starting weight, adherence, dietary changes, activity level, genetics, and other medical factors. These figures should not be interpreted as guaranteed personal outcomes.

Common Side Effects

All four medications share a similar GI side effect profile because of their effect on gastric motility and appetite signaling. The most common side effects include:

• Nausea — most common during dose escalation; typically improves over time
• Vomiting
• Diarrhea
• Constipation
• Abdominal discomfort or bloating
• Injection site reactions (redness, itching)

Serious but less common concerns flagged in prescribing information include: acute pancreatitis, gallbladder disease, and — in animal studies — thyroid C-cell tumors. These medications carry a boxed warning about thyroid C-cell tumors and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).

For full safety information, refer to each medication’s prescribing information: Ozempic ISI | Wegovy ISI | Mounjaro ISI | Zepbound ISI

Cost and Insurance Realities in 2026

All four medications carry significant list prices, ranging from approximately $900 to $1,450 per month at full cost. Insurance coverage is highly variable:

• Ozempic is more commonly covered for T2D patients than for weight loss.
• Wegovy coverage has expanded for patients with established cardiovascular disease, but remains inconsistent for obesity-only coverage.
• Mounjaro is typically covered for T2D; off-label weight loss coverage is rare.
• Zepbound has the clearest pathway for weight management coverage, though plan-by-plan variation remains significant.
• Medicare Part D currently does not cover these medications for weight loss alone (as of mid-2026), though legislative discussions continue.

Novo Nordisk and Eli Lilly both offer savings programs for commercially insured patients. Manufacturer patient assistance programs may apply for uninsured or underinsured patients. Our GLP-1 cost and insurance guide for Georgia patients covers these options in more detail.

How Scale Solutions Helps You Choose

The brand name you arrive with is a starting point for conversation — not a prescription. At Scale Solutions, Dr. Donald L. Gates, MD reviews each patient’s complete clinical picture before recommending a medication:

• Medical history and comorbidities: Type 2 diabetes, prediabetes, cardiovascular disease, PCOS, sleep apnea, and other conditions all influence which medication is most appropriate and which is FDA-approved for your specific situation.
• Contraindications: Personal or family history of MTC, MEN-2, severe gastroparesis, active gallbladder disease, pancreatitis history, pregnancy plans, and eating disorder history must all be screened before prescribing.
• Insurance and cost: The “best” medication is the one you can afford and access consistently — we factor in your real-world coverage situation.
• Tolerability: Patients who don’t tolerate semaglutide well may do better on tirzepatide, or may need a slower titration strategy. There is no single right answer.

Dr. Gates has practiced bariatric medicine since 1999 and brings more than two decades of individualized weight management experience to each consultation. Our practice evaluates patients at three Coastal Georgia locations — Savannah, Pooler, and Hinesville.

See also: GLP-1 weight loss overview | Medical weight loss at Scale Solutions | Full semaglutide vs. tirzepatide comparison guide

Frequently Asked Questions

Is Ozempic approved for weight loss?

Ozempic (semaglutide) is FDA-approved only for type 2 diabetes. It is sometimes prescribed off-label for weight management, but it does not carry an approved weight loss indication. Wegovy — the same molecule at a higher maintenance dose — is the FDA-approved semaglutide product for chronic weight management.

Is Mounjaro the same as Zepbound?

Both contain the same active ingredient, tirzepatide, but they carry different FDA-approved indications. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management (and obstructive sleep apnea). Using Mounjaro for weight loss in a non-diabetic patient is considered off-label use.

Which medication causes the most weight loss?

Based on current clinical trial data, tirzepatide (Zepbound) has demonstrated greater average weight loss in head-to-head comparisons with semaglutide (Wegovy). In the SURMOUNT-5 trial, Zepbound produced approximately 20.2% average weight loss vs. 13.7% with Wegovy at 72 weeks. However, individual results vary, and the best medication for a specific patient depends on their complete clinical picture.

Can I switch from Ozempic to Wegovy or from Mounjaro to Zepbound?

Since each pair shares the same active ingredient, transitions are possible and are managed by a physician who can adjust dosing appropriately. This is a clinical decision that should not be made independently.

How do I know if I qualify for one of these medications?

FDA-approved weight management indications for Wegovy and Zepbound generally require a BMI of 30 kg/m² or higher, or 27 kg/m² or higher with at least one weight-related comorbidity. You can explore eligibility with our BMI and GLP-1 eligibility calculator, and confirm with an in-person evaluation.

Are these medications safe long-term?

These are prescription medications with real risks and benefits. Long-term cardiovascular benefit data exists for semaglutide in specific populations; tirzepatide’s long-term cardiovascular data continues to accumulate. All carry the boxed warning for thyroid C-cell tumors (observed in animals; human risk unclear) and require ongoing physician oversight. Consult the manufacturer prescribing information and speak with a physician before starting any of these medications.

Does Scale Solutions prescribe all four of these medications?

Dr. Gates evaluates each patient individually and recommends the medication that is both clinically appropriate and aligned with your FDA-approval status, insurance situation, and medical history. Contact our practice to discuss your specific situation.